Payment overview · 2025
General Payments
$252.70
12 reported records · 8 companies
Healthcare provider profile · identity verified
Michael P Toney, DO
Allopathic & Osteopathic Physicians|Family Medicine · PIEDMONT, MO · NPI 1407880099
Verified facts
What the public records show
CMS Open Payments records show Michael P Toney, DO received $252.70 in general payments during 2025 across 12 reported records.
Braeburn Inc. accounted for 26.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Xarelto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Braeburn Inc. | Unresolved — no canonical attribution shown | $66.64 | 26.4% | 3 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $35.76 | 14.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.90 | 13.0% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $27.86 | 11.0% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $26.18 | 10.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.59 | 9.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $22.74 | 9.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.03 | 6.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $252.70 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $66.64 | 3 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $35.76 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $27.86 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $26.18 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.59 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22.74 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 450 | 91 |
| Atorvastatin Calcium | Atorvastatin Calcium | 375 | 84 |
| Lisinopril | Lisinopril | 369 | 89 |
| Levothyroxine Sodium | Levothyroxine Sodium | 315 | 55 |
| Omeprazole | Omeprazole | 201 | 37 |
| Potassium Chloride | Potassium Chloride | 195 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 192 | 32 |
| Metformin Hcl | Metformin Hcl | 184 | 39 |
| Gabapentin | Gabapentin | 137 | 32 |
| Losartan Potassium | Losartan Potassium | 133 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 129 | 27 |
| Furosemide | Furosemide | 128 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 125 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 118 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 110 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 107 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 105 | 24 |
| Famotidine | Famotidine | 103 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 103 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 101 | 32 |
| Eliquis | Apixaban | 99 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 98 | 20 |
| Diazepam | Diazepam | 95 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 95 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 84 | 17 |
| Allopurinol | Allopurinol | 82 | 14 |
| Meloxicam | Meloxicam | 70 | 14 |
| Lovastatin | Lovastatin | 69 | 19 |
| Alendronate Sodium | Alendronate Sodium | 66 | 14 |
| Montelukast Sodium | Montelukast Sodium | 65 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 60 | 14 |
| Azithromycin | Azithromycin | 56 | 50 |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 56 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 53 | 14 |
| Simvastatin | Simvastatin | 53 | 13 |
| Prednisone | Prednisone | 52 | 37 |
| Clonidine Hcl | Clonidine Hcl | 51 | suppressed |
| Lorazepam | Lorazepam | 49 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 49 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 11 |
| Finasteride | Finasteride | 48 | suppressed |
| Cephalexin | Cephalexin | 47 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 47 | suppressed |
| Jardiance | Empagliflozin | 46 | suppressed |
| Methylprednisolone | Methylprednisolone | 45 | 42 |
| Memantine Hcl | Memantine Hcl | 44 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 38 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 38 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 31 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 29 | suppressed |
| Carvedilol | Carvedilol | 28 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Lamotrigine | Lamotrigine | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 18 |
| Alprazolam | Alprazolam | 26 | suppressed |
| Cefdinir | Cefdinir | 26 | 24 |
| Tramadol Hcl | Tramadol Hcl | 26 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Risperidone | Risperidone | 25 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 16 | 16 |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Matzim La | Diltiazem Hcl | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Levemir | Insulin Detemir | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $252.70 · 12 records | Braeburn Inc. | BRIXADI, CAPLYTA, Cologuard Collection Kit, MAVYRET, Omnipod, Ozempic, Rybelsus, SPRAVATO, SUBLOCADE, VRAYLAR | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error